摘要
目的探讨门静脉高压症患者行改良脾-肺固定术后血清肝纤维化指标的变化。方法观察2008年6月至2012年12月郑州大学第一附属医院收治的32例行改良脾-肺固定术患者术前及术后6个月血清Ⅲ型胶原(COL-Ⅲ)、Ⅳ型胶原(COL-Ⅳ)、基质金属蛋白酶1(MMP-1)、基质金属蛋白酶组织抑制因子1(TIMP-1)水平,并做统计学比较分析。结果行改良脾-肺固定术后6个月,血清COL-Ⅲ含量由(20.25±3.20)μg/L降至(16.32±2.35)μg/L,COL-Ⅳ由(112.21±23.90)μg/L降至(57.32±18.74)μg/L;血清MMP-1含量由(16.68±8.56)μg/L升至(26.85±8.95)μg/L,TIMP-1由(227.56±76.84)μg/L降至(132.35±62.42)μg/L,各组数据与术前相比均有统计学意义(P<0.01)。结论改良脾-肺固定术可缓解肝脏纤维化进程。
Objective：To evaluate the changes of the serum markers for hepatic fibrogenesis in patients of portal hypertension after modified splenopneumopexy treatment. Methods：From June 2008 to December 2012, 32 patients with portal hypertension were given modified splenopneumopexy in the First Affiliated Hospital of Zhengzhou University. The levels of COL-Ⅲ, COL-Ⅳ, MMP-1, and TIMP-1 were recorded separately before and 6 months after the operation for a statistical comparison. Results：After 6 months, the levels of COL-Ⅲ decreased from （20.25±3.20） μg/L to （16.32±2.35） μg/L, COL-Ⅳ decreased from （112.21±23.90） μg/L to （57.32±18.74） μg/L, the levels of MMP-1 increased from （16.68±8.56） μg/L to （26.85±8.95） μg/L, TIMP-1 decreased from （227.56±76.84） μg/L to （132.35±62.42） μg/L. There were significantly statistical differences between any two groups, P〈0.01. Conclusion：The modified splenopneumopexy helps to slow down the degree of liver fibrosis.
出处
《中华普通外科学文献（电子版）》
2013年第2期31-33,共3页
Chinese Archives of General Surgery(Electronic Edition)
作者简介
通讯作者：党晓卫，Email：dangxw1001@163．com
